AMNEAL PHARMACEUTICALS, INC. (AMRX) Gross margin 2016–2025
AMNEAL PHARMACEUTICALS, INC. (AMRX) gross margin by fiscal year — reported gross profit divided by reported revenue.
36.9%FY2025 · since FY2016: 58.7% → 36.9%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 36.9% | +0.4 pp |
| FY2024 | 36.5% | +2.2 pp |
| FY2023 | 34.3% | -1.2 pp |
| FY2022 | 35.5% | -1.3 pp |
| FY2021 | 36.7% | +5.2 pp |
| FY2020 | 31.5% | +9.8 pp |
| FY2019 | 21.7% | -21.4 pp |
| FY2018 | 43.1% | -7.8 pp |
| FY2017 | 50.9% | -7.8 pp |
| FY2016 | 58.7% | — |
Gross margin = reported gross profit ÷ reported revenue for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More AMRX financial trends
AMRX RevenueAMRX Net incomeAMRX Net marginAMRX Gross profitAMRX Operating incomeAMRX Operating marginAMRX Operating cash flowAMRX Free cash flowAMRX Capital expendituresAMRX Return on equityAMRX Stock buybacksAMRX Dividends paidAMRX Total assetsAMRX Total liabilitiesAMRX Shareholders’ equityAMRX overview →